MadeMed vs MyDrHank
Two GLP-1 desks, one scoreboard. We put MadeMed and MyDrHank head-to-head on the published Brief Score — the same six factors, scored the same way.
MadeMed
The verdict
MadeMed takes this head-to-head.
MadeMed scores 86 to 74 on our six-factor Brief Score — Publishes a price for every dose of every route — which makes it easy to brief, and expensive if you stay low.
That doesn't make MyDrHank a bad call — it's best for readers who already intend to prepay a year up front and want one account covering glp-1 alongside nad+, sermorelin and four other lines — and who will check the term attached to a price before treating it as a monthly bill. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| MadeMed | MyDrHank | |
|---|---|---|
| Brief Score | 86/100 (B) | 74/100 (C) |
| Semaglutide | $239/mo injectable · $219/mo sublingual (quarterly) | $259/mo (month-to-month; prepay tiers lower) |
| Tirzepatide | $399/mo injectable · $299/mo sublingual (quarterly) | $349/mo (month-to-month; prepay tiers lower) |
| Coverage | 40 states | 44 states (not KS, LA, MS, NM, ND, WV) |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
MadeMed: Publishes one price per route that holds at every dose — the cleanest dose-to-price mapping we track.
MyDrHank: First reading. The funnel advertises "from $240" tirzepatide and "from $171" semaglutide; both are twelve-month prepay rungs, and the month-to-month rates — $349 and $259 — appear on no page of it.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.